SEngine Precision Medicine

SEngine Precision Medicine is a biotechnology company that specializes in personalized cancer treatment. The company operates in the healthcare sector, specifically focusing on oncology. SEngine's core service is the PARIS Test, which uses high throughput technology to test over 200 cancer drugs against a patient's unique tumor organoid outside the body. This approach helps identify the most effective and least toxic treatment options, surpassing the capabilities of traditional DNA sequencing. The company serves patients, oncologists, research partners, and pharmaceutical companies. SEngine's business model involves providing actionable reports directly to oncologists, which helps in making informed treatment decisions. The company generates revenue through the sale of its PARIS Test and partnerships with pharmaceutical companies for drug development. SEngine's proprietary platform also leverages aggregated, anonymized test results to aid in the development of new cancer-fighting drugs.

Keywords: personalized cancer treatment, high throughput technology, 3D organoid, PARIS Test, oncology, actionable reports, drug testing, tumor organoid, biotechnology, healthcare.